HC Wainwright & Co. Downgrades Portage Biotech to Neutral
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has downgraded Portage Biotech (NASDAQ:PRTG) from Buy to Neutral, indicating a change in the firm's outlook on the stock.
January 08, 2024 | 6:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Portage Biotech was downgraded by HC Wainwright & Co. from Buy to Neutral, which may influence investors' perception and could affect the stock's performance.
Downgrades by analysts can lead to a negative short term impact on the stock price as they may reflect a less optimistic outlook on the company's future performance or valuation. Investors often consider analyst ratings when making investment decisions.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100